Study of REC-1245 for advanced solid tumors and lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug, REC-1245, for people with advanced solid tumors or certain lymphomas that have not responded to standard treatments. The goal is to see if the drug can shrink tumors or slow disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed advanced solid tumor or lymphoma that has spread or cannot be removed by surgery.
- Your cancer has gotten worse after at least one standard treatment, or you cannot have standard therapy.
- You are generally active and able to take care of yourself (ECOG score 0 or 1, or similar for teens).
- You have measurable tumors that can be seen on a CT scan or MRI.
- You have not taken another drug like REC-1245 that targets RBM39.
- You do not have a significant digestive problem that affects how your body absorbs medicine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called LM-24C5 for people with advanced solid tumors that have stopped responding to standard treatments or who can't tolerate them. It aims to see if the drug is safe and effective.
This trial tests a new drug, SB-4826, for people with advanced solid tumors or certain types of lymphoma that have not responded to standard treatments. The goal is to see if the drug is safe and effective, either alone or with another drug called rituximab.
This trial tests a new drug, ST-01156, designed to attack cancer cells by breaking down a protein called RBM39. It may be an option for people with advanced solid tumors that have not responded to other treatments.
This study tests a new drug called REC-617 in patients with a rare muscle cancer (leiomyosarcoma) that has spread or cannot be surgically removed. The drug targets cancer cells that lack a specific protein called RB1, and you must have already tried at least one other cancer treatment before joining.
This Phase 1/2 study tests an experimental medicine (RNK05047) in people with advanced solid tumors or diffuse large B‑cell lymphoma whose standard treatments haven’t worked or can’t be tolerated. It may help shrink tumors and improve control of the disease, but early-phase trials also focus on safety and dosing.
This trial tests a new drug called LRK-4189, alone or with other treatments, for people with advanced solid tumors that have worsened despite prior therapy. The goal is to see if it is safe, tolerable, and helpful against the cancer.
Hear when a new Unresectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.